These findings not only provide insights into the pathophysiology of CVID, but also reveal novel pathways for further investigations, and may hence help to develop targeted therapy strategies for patients with mutations in TNFRSF13B. This evidence concerns the gene TNFRSF13B and common variable immunodeficiency.